<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970916</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-16-02</org_study_id>
    <nct_id>NCT02970916</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms</brief_title>
  <acronym>POLAF</acronym>
  <official_title>A Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or
      without ACE polymorphisms in terms of Progression-free survival (PFS).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FOLFIRI+aflibercept efficacy in terms of Progression-free survival (PFS) with or without ACE polymorphisms.</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) with or without AGTR1 polymorphisms, according Serum-level sACE</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TP) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) with or without ACE polymorphisms, AGTR1 polymorphisms, according Serum-level sACE</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as assessed by CTCAE v4.0.</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma VEGF levels circulating and their correlation with tumour-efficacy parameters (ORR, PFS and OS)</measure>
    <time_frame>30 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Other biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with tumour-efficacy parameters (ORR, PFS and OS)</measure>
    <time_frame>30 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI+aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI+aflibercept</intervention_name>
    <description>Aflibercept: 4 mg/kg administered intravenous infusion on day 1
FOLFIRI regimen immediately after aflibercept:
Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.
* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)</description>
    <arm_group_label>FOLFIRI+aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent, and willing and able to comply with protocol
             requirements,

          2. Histologically proven adenocarcinoma of the colon and/or rectum,

          3. Metastatic disease confirmed.

          4. Existence of at least one measurable unidimensional lesion using CT or MRI based on
             the RECIST criteria, version 1.1

          5. Patients with metastatic colorectal cancer (mCRC) that is resistant to or has
             progressed after an oxaliplatin-containing regimen.

          6. Age ≥18 years

          7. World Health Organization (WHO) Performance status (PS) 0-2,

          8. Hematological status: neutrophils (ANC) ≥1.5x109 /L; platelets ≥100x109 /L;
             haemoglobin ≥9g/dL

          9. Adequate renal function: serum creatinine level &lt; 1.5 x ULN

         10. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alkaline
             phosphatase (ALP) &lt;5xULN

         11. Proteinuria &lt;2+ (dipstick urinalysis) or ≤1g/24hour.

         12. Regular follow-up feasible.

         13. For female patients of childbearing potential, negative serum pregnancy test

         14. Female patients must commit to using reliable and appropriate methods of contraception
             until at least three months after the end of study treatment (when applicable). Male
             patients with a partner of childbearing potential must agree to use contraception in
             addition to having their partner use another contraceptive method during the trial.

        Exclusion Criteria:

          1. Uncontrolled hypercalcemia,

          2. Pre-existing permanent neuropathy (NCI grade &gt;2)

          3. Uncontrolled hypertension (defined as systolic blood pressure &gt;150 mmHg and/or
             diastolic blood pressure &gt;100 mmHg), or history of hypertensive crisis, or
             hypertensive ncephalopathy,

          4. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular
             targeted therapy, immunotherapy),

          5. Treatment with any other investigational medicinal product within 28 days prior to
             study entry.

          6. Other serious and uncontrolled non-malignant disease,

          7. History or evidence upon physical examination of CNS metastasis unless adequately
             treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard
             medical therapy),

          8. Known Gilbert's syndrome

          9. Intolerance to atropine sulfate or loperamide

         10. Known dihydropyrimidine dehydrogenase deficiency

         11. Treatment with CYP3A4 inducers unless discontinued &gt; 7 days prior to inclusion

         12. Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal
             bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease,
             erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or
             diverticulitis.

         13. Other concomitant or previous malignancy, except: i/ adequately treated insitu
             carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin,
             iii/ cancer in complete remission for &gt;5 years,

         14. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic
             injury within the last 28 days

         15. Pregnant or breastfeeding women,

         16. Patients with known allergy to any excipient to study drugs,

         17. History of myocardial infarction and/or stroke within 6 months prior to inclusion,
             NYHA class III and IV congestive heart failure

         18. Bowel obstruction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Aranda, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Auxiliadora Gómez, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for the Treatment of Digestive Tumors</name>
      <address>
        <city>Madrona</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>aflibercept</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>ACE polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

